Mavatar
June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste.
Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.
Company HQ City:
Stockholm
Company HQ State:
Stockholm, Sweden
Company HQ Country:
Sweden
Year Founded:
2018
Lead Product in Development:
We have two flagship platforms:
• Mavatar Discovery – accelerating disease and drug research (currently in BETA, full commercial launch Sep, 2025)
• Mavatar Precision – guiding clinicians to more accurate treatment decisions (Launch 2026)
CEO
Johan Juhlin
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
Mavatar Discovery is a research-focused platform and does not fall under medical device regulations. It is intended for use by scientists, pharmaceutical companies, and research institutions for non-clinical applications.
Our clinical platform, Mavatar Precision, which supports personalized treatment decisions, is currently in development. We plan to pursue FDA approval in 2026 as part of our regulatory strategy for broader clinical adoption.
When you expect your next catalyst update?
Mavatar is currently raising a $12 million investment round to support the commercial launch of our first platform, Mavatar Discovery, which is currently in closed BETA and will roll out publicly in June, with full release in September. This launch marks a major inflection point as we transition from development to commercialization—unlocking SaaS revenue, expanding industry collaborations, and accelerating growth.
Additionally, we are preparing our clinical platform, Mavatar Precision, for FDA submission in 2026, establishing a second high-value milestone in our path to transforming patient care.
In parallel, we are advancing Mavatar Precision development, moving toward clinical validation, with FDA regulatory planning underway for submission in 2026—positioning us for a second major inflection point in the clinical space.
What is your next catalyst (value inflection) update?
Fundraising and launch of Mavatar Discovery between June - Sep 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}